Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial (Nurmi et al. Journal of Infection, 9;90(2):106412. January 2025)
Initial efforts to curve the spread and severity of Covid-19 involved convalescent plasma treatment — the transfusion of antibodies from recovered COVID-19 patients.
In this study, we analyzed the outcomes of a major clinical trial, REMAP-CAP, and found that convalescent plasma had limited effectiveness. The "high titre" plasma used had surprisingly low potency compared to patients' natural immune responses.
Despite this, convalescent plasma could still be useful in future pandemics, particularly if given early, i.e. soon after the onset of symptoms.
The publication can be found at: 10.1016/j.jinf.2025.106412